Pivotal Pulmonary Arterial Hypertension Study Published in The Lancet Concludes That Bosentan (Tracleer(R)) Demonstrates Benefits in Patients With Mildly Symptomatic WHO Functional Class ...(arterial hypertension. Circulation...),Health

Circulation 2005; 111: 3105-3111

5. D'Alonzo GE, Barst RJ, Ayres SM et al. Survival in patients with

primary pulmonary hypertension: Results from a national prospective

registry. Ann Intern Med 1991; 115: 343-349.

6. Barst RJ, McGoon M, Torbicki A et al. Diagnosis and differential

assessment of pulmonary arterial hypertension. J Am Coll Cardiol 2004;

43(Suppl S): 40S-47S

Actelion Ltd

Actelion Ltd is a biopharmaceutical company with its corporate headquarters in Allschwil/Basel, Switzerland. Actelion's first drug Tracleer(R), an orally available dual endothelin receptor antagonist, has been approved as a therapy for pulmonary arterial hypertension. Actelion markets Tracleer(R) through its own subsidiaries in key markets worldwide, including the United States (based in South San Francisco), the European Union, Japan, Canada, Australia and Switzerland. Actelion, founded in late 1997, is a leading player in innovative science related to the endothelium -- the single layer of cells separating every blood vessel from the blood stream. Actelion's over 1700 employees focus on the discovery, development and marketing of innovative drugs for significant unmet medical needs. Actelion shares are traded on the SWX Swiss Exchange (ticker symbol: ATLN).